Literature DB >> 8357778

Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study.

N Corsico1, A Nardone, M R Lucreziotti, L G Spagnoli, D Pesce, T Aureli, M E Di Cocco, A Miccheli, F Conti, E Arrigoni Martelli.   

Abstract

Propionyl-L-carnitine (PLC) has been shown to exert beneficial effects in experimental models of peripheral arterial diseases, such as ergotamine-induced tail gangrene and bilateral femoral arteries occlusion in rats. These models, however, present some drawbacks. The present study was performed to determine whether repeated oral administration of PLC improves the functional, histologic, and metabolic parameters in rats with long-lasting chemically induced peripheral arteriopathy. Peripheral arteriopathy was induced by injecting Na laurate in both the femoral arteries of rats. The walking capacity of the animals (treadmill test) was evaluated at different times and up to 5 weeks after Na laurate injection. Histological examination of vessels and muscles was performed at the end of the experimental period (5 weeks). In separate experiments the level of high-energy phosphates was determined with 31P NMR methodology in the leg muscles. Injection of Na laurate impaired (p < 0.05) the walking capacity of rats, caused thickening of the intima and marked narrowing of the vasal lumen, and reduced the ATP and PCr levels in muscles by 42% and 25%, respectively. PLC given orally for 7 days at 30, 60, 120, and 250 mg/kg dose-dependently decreased the severity of walking capacity impairment by 19%, 41%, 64%, and 71%, respectively. Long-term administration (4 weeks) of PLC (60 and 250 mg/kg os) caused a significant improvement of walking capacity throughout the entire period. The improvement persisted 1 week after discontinuation of the treatment. The severity of the vascular and muscular damages was markedly reduced, particularly in animals treated with the highest dose. Alterations in ATP and PCr levels were significantly (p < 0.05) diminished by PLC (120 mg/kg os) administered daily for 15 days starting 24 hours after Na laurate injection, or for 11 days starting 4 days after Na laurate. The dextro-isomer of the compound was completely inactive, and L-carnitine improved motor performance to a much lesser degree than an identical dose of PLC. It is suggested that the activity of PLC is linked to its metabolic effects on fatty acid oxidation, with consequent preservation of high-energy phosphate levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8357778     DOI: 10.1007/bf00878514

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  31 in total

1.  Demonstration of all connective tissue elements in a single section; pentachrome stains.

Authors:  H Z MOVAT
Journal:  AMA Arch Pathol       Date:  1955-09

2.  Protective effect of propionyl-L-carnitine against ischaemia and reperfusion-damage.

Authors:  R Ferrari; C Ceconi; S Curello; E Pasini; O Visioli
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

3.  Influence of training following bilateral stenosis of the femoral artery in rats.

Authors:  G M Mathien; R L Terjung
Journal:  Am J Physiol       Date:  1986-06

4.  Study on influence of inactivation enzyme techniques and extraction procedures on cerebral phosphorylated metabolite levels by 31P NMR spectroscopy.

Authors:  A Miccheli; T Aureli; M Delfini; M E Di Cocco; P Viola; R Gobetto; F Conti
Journal:  Cell Mol Biol       Date:  1988       Impact factor: 1.770

5.  Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study.

Authors:  G Brevetti; S Perna; C Sabbà; A Rossini; V Scotto di Uccio; E Berardi; L Godi
Journal:  Eur Heart J       Date:  1992-02       Impact factor: 29.983

6.  Carnitine metabolism during exercise in patients with peripheral vascular disease.

Authors:  W R Hiatt; D Nawaz; E P Brass
Journal:  J Appl Physiol (1985)       Date:  1987-06

7.  Propionyl carnitine in stable effort angina.

Authors:  A Cherchi; C Lai; E Onnis; E Orani; R Pirisi; M R Pisano; A Soro; M Corsi
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

8.  Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.

Authors:  G Brevetti; M Chiariello; G Ferulano; A Policicchio; E Nevola; A Rossini; T Attisano; G Ambrosio; N Siliprandi; C Angelini
Journal:  Circulation       Date:  1988-04       Impact factor: 29.690

9.  Carnitine transport and exogenous palmitate oxidation in chronically volume-overloaded rat hearts.

Authors:  Z el Alaoui-Talibi; J Moravec
Journal:  Biochim Biophys Acta       Date:  1989-06-08

10.  Effects of L-propionylcarnitine on mechanical recovery during reflow in intact hearts.

Authors:  A J Liedtke; L DeMaison; S H Nellis
Journal:  Am J Physiol       Date:  1988-07
View more
  3 in total

Review 1.  Propionyl-L-carnitine.

Authors:  L R Wiseman; R N Brogden
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

2.  Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication.

Authors:  Antonio Strano
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

3.  Effect of propionyl-L-carnitine treatment on membrane phospholipid fatty acid turnover in diabetic rat erythrocytes.

Authors:  A Arduini; S Dottori; A F Sciarroni; N Corsico; E Morabito; E Arrigoni-Martelli; M Calvani
Journal:  Mol Cell Biochem       Date:  1995-11-08       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.